Zacks Investment Research upgraded shares of Catalent, Inc. (NYSE:CTLT) from a hold rating to a buy rating in a research note released on Monday, November 6th. They currently have $48.00 price objective on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
CTLT has been the topic of a number of other research reports. Bank of America Corporation reaffirmed a buy rating and issued a $40.00 target price (up previously from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. William Blair reaffirmed an ourperform rating on shares of Catalent in a research note on Tuesday, August 29th. Piper Jaffray Companies reaffirmed a buy rating and issued a $45.00 target price on shares of Catalent in a research note on Tuesday, August 29th. ValuEngine raised Catalent from a hold rating to a buy rating in a research note on Thursday, September 7th. Finally, Wells Fargo & Company reaffirmed an outperform rating and issued a $39.00 target price (up previously from $30.00) on shares of Catalent in a research note on Thursday, August 31st. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Catalent presently has an average rating of Buy and an average price target of $42.11.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.16 EPS. sell-side analysts expect that Catalent will post 1.46 EPS for the current year.
In other Catalent news, Director Uwe Roehrhoff purchased 7,500 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was bought at an average cost of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Janus Henderson Group PLC acquired a new position in Catalent in the 2nd quarter valued at $239,629,000. BlackRock Inc. raised its holdings in Catalent by 15.2% in the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock valued at $614,695,000 after acquiring an additional 2,316,849 shares during the last quarter. Eagle Asset Management Inc. raised its holdings in Catalent by 290.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock valued at $47,636,000 after acquiring an additional 858,600 shares during the last quarter. AJO LP acquired a new position in Catalent in the 2nd quarter valued at $26,130,000. Finally, Macquarie Group Ltd. raised its holdings in Catalent by 60.2% in the 2nd quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock valued at $62,715,000 after acquiring an additional 671,429 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Catalent, Inc. (NASDAQ:CTLT) Upgraded at Zacks Investment Research” was reported by BBNS and is the sole property of of BBNS. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/catalent-inc-ctlt-upgraded-by-zacks-investment-research-to-buy/1762381.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with our FREE daily email newsletter.